Results of the PEACE-1 open-label, randomized, controlled, phase III trial have been published in The Lancet. In this study, the efficacy and safety of adding prostate radiotherapy to the treatment regimen in de novo metastatic castration-sensitive prostate cancer was investigated. In total, 1,172 men were randomly assigned to receive standard of care or standard of care plus abiraterone, plus radiotherapy or plus abiraterone and radiotherapy. After a median follow-up duration of 6 years, radiographic progression-free and castration-free survival were improved for men who received standard of care plus abiraterone and radiotherapy. However, overall survival was not affected.
